1665-47-0

Usage

Uses

Used in Pharmaceutical Industry:
N-BENZYL-3-BROMOPROPANAMIDE is used as a chemical intermediate for the synthesis of various pharmaceuticals. Its unique structure allows it to be a key component in the development of new drugs, contributing to the advancement of medical treatments.
Used in Agrochemical Industry:
In the agrochemical sector, N-BENZYL-3-BROMOPROPANAMIDE serves as an intermediate in the production of agrochemicals. Its role in creating effective compounds for agricultural applications helps improve crop protection and yield.
Storage and Handling:
N-BENZYL-3-BROMOPROPANAMIDE should be carefully handled and stored in a cool, dry, and well-ventilated area to maintain its stability and purity. It must be kept away from heat, flame, and sources of ignition to prevent any hazardous reactions. Additionally, it should be protected from light and kept in a tightly closed container to avoid contamination or degradation, ensuring its integrity for use in various applications.

InChI:InChI=1/C10H12BrNO/c11-7-6-10(13)12-8-9-4-2-1-3-5-9/h1-5H,6-8H2,(H,12,13)

Upstream product

• 15486-96-1 3-Bromopropionyl chloride 
• 100-46-9 benzylamine 
• 7623-16-7 3-bromopropionyl bromide 

Downstream Products

• 4458-64-4 N-benzyl-2-azetidinone 
• 100861-67-4 N,N-diethyl-β-alanine benzylamide 
• 13304-62-6 N-benzylacrylamide 
• 109389-01-7 4-(N-benzylcarbamoylethoxy)-2-methylthiopyrimidine 
• 109389-03-9 4-(N-benzylcarbamoylethoxy)-6-methyl-2-methylthiopyrimidine 
• 80578-25-2 3-benzyl-3,4,5,6-tetrahydro-2H-1,3-oxazine-2,4-dione 
• 470678-28-5 benzyl-(3-bromo-propionyl)-carbamic acid benzyl ester 
• 60536-21-2 10-benzylacridine-9(10H)-one 
• 1244550-43-3 C₂₇H₂₂N₄O₅ 
• 1243283-98-8 N-benzyl-3-[(2R,6R,11R)-8-hydroxy-6,11-dimethyl-1,4,5,6-tetrahydro-2,6-methano-3-benzazocin-3(2H)-yl]propanamide 
• 470677-97-5 benzyl-(3-bromo-1-trimethylsilanyloxy-propyl)-carbamic acid benzyl ester 

Relevant academic research and scientific papers

Synthesis of pyrimido[2,1-a]isoindolone and isoindolo[2,1-a]quinazolinoneviaintramolecular aza-Prins type reaction

A novel aza-Prins type cyclization reaction involvingN-acyliminium ions and amides is reported for the synthesis of tetrahydropyrimido[2,1-a]isoindole-2,6-dione and 6,6a-dihydroisoindolo[2,1-a]quinazoline-5,11-dione derivatives in excellent yields. The strategy features inexpensive reagents, mild reaction conditions, and metal-free synthesis of N-heterocyclic frameworks. Further, post-synthetic modification results in the unprecedented formation of its triazole, tetracyclic diazacyclopenta[def]phenanthrene-1,4(9a1H)-dione and carbonyl derivatives.

Novel Multitarget-Directed Ligands Aiming at Symptoms and Causes of Alzheimer's Disease

Alzheimer's disease (AD) is a major public health problem, which is due to its increasing prevalence and lack of effective therapy or diagnostics. The complexity of the AD pathomechanism requires complex treatment, e.g. multifunctional ligands targeting both the causes and symptoms of the disease. Here, we present new multitarget-directed ligands combining pharmacophore fragments that provide a blockade of serotonin 5-HT6 receptors, acetyl/butyrylcholinesterase inhibition, and amyloid β antiaggregation activity. Compound 12 has displayed balanced activity as an antagonist of 5-HT6 receptors (Ki = 18 nM) and noncompetitive inhibitor of cholinesterases (IC50hAChE = 14 nM, IC50eqBuChE = 22 nM). In further in vitro studies, compound 12 has shown amyloid β antiaggregation activity (IC50 = 1.27 μM) and ability to permeate through the blood-brain barrier. The presented findings may provide an excellent starting point for further studies and facilitate efforts to develop new effective anti-AD therapy.

Formation of acridones by ethylene extrusion in the reaction of arynes with β-lactams and dihydroquinolinones

N-Unsubstituted β-lactams react with a molecule of aryne by insertion into the amide bond to form a 2,3-dihydroquinolin-4-one, which subsequently reacts with another molecule of aryne to form an acridone by extrusion of a molecule of ethylene. 2,3-Dihydroquinolin-4-ones react under the same reaction conditions to afford identical results. This is the first example of ethylene extrusion in aryne chemistry.

Evaluation of N-substitution in 6,7-benzomorphan compounds

6,7-Benzomorphan derivatives, exhibiting different μ, δ, and κ receptor selectivity profiles depending on the N-substituent, represent a useful skeleton for the synthesis of new and better analgesic agents. In this work, an aromatic ring and/or alkyl residues have been used with an N-propanamide or N-acetamide spacer for the synthesis of a new series of 5,9-dimethyl-2′-hydroxy-6,7-benzomorphan derivatives (12-22). Data obtained by competition binding assays showed that the μ opioid receptor seems to prefer an interaction with the 6,7-benzomorphan ligands having an N-substituent with a propanamide spacer and less hindered amide. Highly stringent features are required for δ receptor interaction, while an N-acetamide spacer and/or bulkier amide could preferentially lead to κ receptor selectivity. In the propanamide series, compound 12 (named LP1) displayed high μ affinity (Ki = 0.83 nM), good δ affinity (Ki = 29 nM) and low affinity for the κ receptor (Ki = 110 nM), with a selectivity ratio δ/μ and κ/μ of 35.1 and 132.5, respectively. Further, in the adenylyl cyclase assay, LP1 displayed a μ/δ agonist profile, with IC50 values of 4.8 and 12 nM at the μ and δ receptors, respectively. The antinociceptive potency of LP1 in the tail-flick test after sc administration in rat was comparable with the potency of morphine (ED50 = 2.03 and 2.7 mg/kg, respectively), and was totally reversed by naloxone. LP1, possessing a μ/δ agonist profile, could represent a lead in further developing benzomorphan-based ligands with potent in vivo analgesic activity and a reduced tendency to induce side effects.

Targeting mycobacterium protein tyrosine phosphatase B for antituberculosis agents

Protein tyrosine phosphatases are often exploited and subverted by pathogenic bacteria to cause human diseases. The tyrosine phosphatase mPTPB from Mycobacterium tuberculosis is an essential virulence factor that is secreted by the bacterium into the cytoplasm of macrophages, where it mediates mycobacterial survival in the host. Consequently, there is considerable interest in understanding the mechanism by which mPTPB evades the host immune responses, and in developing potent and selective mPTPB inhibitors as unique antituberculosis (antiTB) agents. We uncovered that mPTPB subverts the innate immune responses by blocking the ERK1/2 and p38 mediated IL-6 production and promoting host cell survival by activating the Akt pathway. We identified a potent and selective mPTPB inhibitor I-A09 with highly efficacious cellular activity, from a combinatorial library of bidentate benzofuran salicylic acid derivatives assembled by click chemistry. We demonstrated that inhibition of mPTPB with I-A09 in macrophages reverses the altered host immune responses induced by the bacterial phosphatase and prevents TB growth in host cells. The results provide the necessary proof-of-principle data to support the notion that specific inhibitors of the mPTPB may serve as effective antiTB therapeutics.

Derivatives of salicylic acid as inhibitors of YopH in yersinia pestis

Yersinia pestis causes diseases ranging from gastrointestinal syndromes to bubonic plague and could be misused as a biological weapon. As its protein tyrosine phosphatase YopH has already been demonstrated as a potential drug target, we have developed two series of forty salicylic acid derivatives and found sixteen to have micromolar inhibitory activity. We designed these ligands to have two chemical moieties connected by a flexible hydrocarbon linker to target two pockets in the active site of the protein to achieve binding affinity and selectivity. One moiety possessed the salicylic acid core intending to target the phosphotyrosine-binding pocket. The other moiety contained different chemical fragments meant to target a nearby secondary pocket. The two series of compounds differed by having hydrocarbon linkers with different lengths. Before experimental co-crystal structures are available, we have performed molecular docking to predict how these compounds might bind to the protein and to generate structural models for performing binding affinity calculation to aid future optimization of these series of compounds.

Synthesis of substituted 2-amino-5,6-dihydropyrimidin-4-ones using an aza-Wittig reaction

An aza-Wittig reaction has been used for the first time in the synthesis of substituted 2-amino-5,6-dihydropyrimidin-4-ones via condensation of triphenyliminophosphoranes with aromatic heterocumulenes (arylisocyanates and thiocyanates).

β-Lactam compounds

A compound of formula (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof: STR1 wherein R represents an alkyl or aralkyl group, substituted on an alkyl carbon atom other than that adjacent to --NH-- group, with one or more functional groups selected from halogen, non-aromatic heterocyclyl linked through carbon, aromatic heterocyclyl, nitro, oxo, --OR1, SR1 --P(O)R2 R3, --NR4 R5, =NR6, or a sulphur linked organic radical, wherein R1, R2, R3, R4, R5 and R6 are various organic radicals. Processes for the preparation of these compounds and pharmaceutical compositions containing them are also disclosed.

A Convenient Synthesis of Monocyclic β-Lactams by Means of Solid-Liquid Phase Transfer Reactions

The intramolecular N-alkylation of β-bromopropionamides (1) under phase transfer conditions afforded monocyclic N-substituted β-lactams (2) in high yields.In a similar manner, cyclization by N1-C4 bond formation gave 4-benzoyl-2-azet